43.55 0.00 (0.01%)
After hours: 4:26PM EST
|Bid||43.56 x 3200|
|Ask||43.58 x 3000|
|Day's Range||43.31 - 43.69|
|52 Week Range||38.43 - 48.25|
|Beta (5Y Monthly)||0.34|
|PE Ratio (TTM)||43.90|
|Forward Dividend & Yield||2.40 (5.48%)|
|Ex-Dividend Date||Feb 19, 2020|
|1y Target Est||N/A|
Shares of Glaxo (GSK) lag the industry in a year as generic erosion of some drugs mainly its top-selling drug, Advair offsets strong sales of new drugs.
Pfizer stock is on a recent downswing in the wake of lackluster fourth-quarter earnings. But shares are consolidating on the weekly chart. Is the pharmaceutical company a buy right now?
The life sciences industry is no doubt big business in North Carolina with more than 735 bioscience companies and a total of more than 66,000 industry workers. And the Triangle has its fair share of that pie. Bio/pharma companies are the focus of one of this week’s Triangle Business Journal lists.
Income investors can leverage the increased demand for healthcare into strong total returns, explains Ned Piplovic, editor of DividendInvestor. Here, he reviews two global pharmaceutical firms that are attractive for investors seeking both growth and income.
Shortages and potential price increases of generic drugs from India loom if the coronavirus outbreak disrupts suppliers of pharmaceutical ingredients in China past April, according to industry experts. An important supplier of generic drugs to the world, Indian companies procure almost 70% of the active pharmaceutical ingredients (APIs) for their medicines from China. India's generic drugmakers say they currently have enough API supplies from China to cover their operations for up to about three months.
A passenger who was repatriated from Wuhan, China, on a U.S. flight and has been in quarantine in San Diego is the latest individual in the U.S. to test positive for the coronavirus, according to media reports.
GlaxoSmithKline plc (LON:GSK) shares fell 4.7% to UK£17.00 in the week since its latest yearly results. The result was...
GlaxoSmithKline shares lost ground on Thursday for a second day as brokers reacted cautiously to the U.K. pharmaceutical’s outlook.
French drugmaker Sanofi will announce a new coronavirus initiative within the next two weeks, its chief executive said on Thursday, adding that it wants to present something concrete and not add to "fantasies". "We have seen a flurry of activities from other companies," CEO Paul Hudson told a news conference after Sanofi published 2019 results on Thursday. Hudson declined to give further details.
GlaxoSmithKline plans to spin off its consumer health care business, leading GSK stock to slip at the close. The new GSK focuses on the immune system, genetics and new technologies,
Drugmakers racing to find a vaccine or effective treatment for the deadly new coronavirus in China cautioned that they have a long way to go. At least a dozen drugmakers are working on vaccines or antivirals and other treatments to help those infected with the fast-spreading contagion. Investment costs for vaccines could run as high as $800 million in a process that, even if accelerated, will likely take more than a year until approval, according to executives from companies involved in the effort.
VBI Vaccines' (NASDAQ:VBIV) stock is on the move. The shares have rallied on the heels of a successful clinical trial. But is it too late to buy the stock?While VBIV has soared around 130% since Nov. 1, more gains could be in the cards. Everything hinges on the company being able to market its Sci-B-Vac hepatitis vaccine in North America and Europe. Source: ravipat/Shutterstock.com VBIV stock is dependent on Sci-B-Vac. There are other drugs in the company's pipeline. But Sci-B-Vac is the only one that's ready for prime time. The company could win big if the vaccine is approved by the key regulators. However, if the company hits additional headwinds, the shares could crash back to their prior lows.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBut despite its high risk, VBIV stock may be worth buying at today's prices. The excitement from the results of the Phase 3 trial of Sci-B-Vac has cooled off, sending the shares lower in the past few weeks. This could mean that the shares have reached a solid entry point. Let's see why this high-risk/high-return stock may be a great investment. With Sci-B-Vac's Success More Certain, VBIV Stock Could Head HigherThe success of the company's recent Phase 3 trial bodes well for VBIV stock. But it's important to consider the mixed outcome of the company's prior clinical trial. As InvestorPlace contributor Chris Markoch noted in a recent column, this was Sci-B-Vac's second Phase 3 trial. Back in June, the company completed its initial Phase 3 trial. * 7 Utility Stocks to Buy That Offer Juicy Dividends Based on the outcome of the latter trial, Sci-B-Vac appeared to be more effective than GlaxoSmithKline's (NYSE:GSK) Energix-B. Yet, as Markoch pointed out, " the trial showed that Sci-B-Vac taken in two doses was not as effective as Engerix-B taken in three doses." VBIV stock crashed as investors became less optimistic about Sci-B-Vac's future prospects.But, after this second trial, Sci-B-Vac's viability as a two-dose vaccine is more certain. The second trial's results showed that two doses of Sci-B-Vac were more effective than Energix-B. Thanks to these results, the company plans to seek North American and European approvals in the second half of 2020.What's now key for VBIV stock is how Sci-B-Vac fares against Dynavax's (NASDAQ:DVAX) Heplisav-B. According to a Seeking Alpha contributor, Heplisav-B's key selling point is that it's a two-dose vaccine., while VBIV plans to market its vaccine as a three-dose treatment. But Heplisav-B has had its own headwinds. Rejected twice due to safety concerns by the FDA, Heplisav-B was finally approved in late 2017.Can Sci-B-Vac gain an edge against Heplisav-B? With Heplisav-B already on the market in North America, Dynavax has first-mover advantage over VBIV. But, with VBIV likely to partner with a big pharma company and Dynavax, "going it alone," Sci-B-Vac could wind up having stronger marketing infrastructure behind it.Yet VBIV stock is facing some key risks. Dilution Is Likely, But That's Par for the CourseAs of VBI's last quarterly filing, the company had $53 million of cash. But, given its $54.2 million of operating losses over the previous year, it will need more money going forward, especially since the company is trying to bring Sci-B-Vac to market.Partnering with a big pharma company could minimize its cash burn. However, VBIV appears likely to issue more stock, diluting the value of its shares.But, to monetize Sci-B-Vac, the company needs cash. In the end, a dilutive equity infusion will allow VBIV to fully monetize Sci-B-Vac, ultimately sending the shares higher.As mentioned above, VBIV stock is dependent on a sole catalyst. The success or failure of Sci-B-Vac will drive the future direction of the shares. VBI Vaccines does have other opportunities in its pipeline. These include a chronic hepatitis B infection treatment, as well as a immunotherapy treatment for glioblastoma. But don't expect these drugs to move the needle anytime soon, as both are in the early development stages. The Bottom LineVBIV stock is a high-risk/high-return investment. If Sci-B-Vac is approved by the FDA, the shares could move higher. But, if Sci-B-Vac is not approved, the stock could fall significantly. Yet, with analysts' average price target on the shares standingt at $4.50, VBIV may be worth the risk.After the results of the Phase 3 trial were announced, VBIV stock soared as high as $1.90 per /share. But, after investors' excitement cooled, the shares have slid back to around $1.50. Although the shares are up from their past lows, now may be a great time to buy them.VBIV stock is not a "bet the ranch" situation. But the shares could rally tremendously in the next year. With potential approvals of its vaccine in North America and Europe on the horizon, VBIV could be a big winner in 2020.As of this writing, Thomas Niel did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Utility Stocks to Buy That Offer Juicy Dividends * 10 Gold and Silver Stocks to Profit Off 2020's Fear Trade * 3 Top Companies That Should Be More Careful With Your Data The post While Risks Remain, VBI Vaccines Stock Is a Buy at Today's Prices appeared first on InvestorPlace.
GSK shares fell as much as 3% after the company also said adjusted earnings for this year could fall as much as 4%. Under Chief Executive Emma Walmsley, the London-listed firm has sold several assets, and bought others in fast-growing markets such as oncology, to try to rejuvenate growth as several of its older drugs face losing patent protection. Vaccines and prescription treatments including for HIV will play a larger role in driving GSK's growth going forward as older treatments, including asthma drug Advair, face competition from generic medicines.
Theravance's (TBPH) COPD drug Yupelri witnesses a strong adoption while its pipeline programs make a steady progress. However, high reliance on Yupelri for revenues is a concern.
Glaxo misses both earnings and sales estimates in the fourth quarter of 2019. The company initiates separation program to split itself into two standalone units. Stock down.
U.K. pharmaceutical giant GlaxoSmithKline said fourth-quarter adjusted earnings per share fell 21% to 24.8 pence, while revenue rose 9% to £8.9 billion, as it also said it's planning to split into two companies in two years. Analysts polled by FactSet expected an EPS of 25.5 pence on revenue of £9 billion. Glaxo cited an increased non-controlling interest allocation of consumer healthcare profits and increased net finance costs, partly offset by a reduced effective tax rate, for the EPS decline. Revenue rose on the vaccine business as well as the acquisition of Pfizer's consumer healthcare business. Glaxo says it expects adjusted EPS to fall between 1% and 4% at constant exchange rates for 2020, and is expecting to pay an 80 pence dividend. Glaxo said it will divide into an immune system-focused biopharma and a consumer healthcare company, and preparation costs will be between £600 million and £700 million. London-listed Glaxo shares slipped 0.2%.
UK drugmaker GlaxoSmithKline has warned that profits will suffer as it steps up investment in research and product launches in an effort to revitalise its pipeline. The comments came as GSK posted annual results on Wednesday that showed full-year sales rose 8 per cent year on year to £33.8bn, in line with expectations. Adjusted earnings per share in 2019 rose 4 per cent to 123.9p, below consensus expectations of 125p.